利妥昔单抗联合低剂量环磷酰胺和泼尼松治疗膜性肾病
该单臂前瞻性队列研究纳入26例高危、抗PLA2R抗体阳性的膜性肾病患者,采用利妥昔单抗联合低剂量环磷酰胺和泼尼松的三联方案。结果显示8周内免疫学缓解率达88%,多数患者获得蛋白尿缓解,基线PLA2R抗体水平和抗体半衰期与缓解相关。
要点
- 低剂量三联方案在高危PLA2R抗体阳性膜性肾病中诱导快速免疫学和临床缓解。
- 基线PLA2R抗体滴度高和抗体半衰期长提示临床反应不足。
- 治疗开始后2-4周评估PLA2R抗体水平有助于识别需更强治疗的患者。
核心结论
- 低剂量三联疗法在多数高危PLA2R抗体阳性膜性肾病患者中诱导快速的免疫学和临床缓解。
- 临床反应不足的患者特征为基线PLA2R抗体水平高和PLA2R抗体半衰期长。
研究设计与样本
- 单臂前瞻性队列研究,纳入26例高危、抗PLA2R抗体阳性的膜性肾病患者。
- 治疗方案:利妥昔单抗2×1000 mg,环磷酰胺1.5 mg/kg/d×8周,泼尼松(静脉2×1 g+口服3周起始1 mg/kg)。
- 定期监测PLA2R抗体水平,报告抗体动力学及总体免疫学和临床缓解率。
主要发现
- 26例患者中15例男性,年龄57±14岁,PLA2R抗体滴度176(115-460)RU/ml,血肌酐128(102-136)μmol/l,血清白蛋白18(14-21)g/l,尿蛋白肌酐比7.1(5.7-10)g/10 mmol。
- 8周内免疫学缓解(ELISA<14 RU/ml)率为88%。
- 初始治疗后21例患者出现蛋白尿缓解;7例接受再次治疗,均获得蛋白尿缓解。
- 免疫学和临床缓解与基线PLA2R抗体三分位分组相关。
- 7例需额外治疗的患者中,5例在治疗开始后4周通过PLA2R抗体半衰期>7天被识别。
关键数值与推荐
- 免疫学缓解定义为ELISA检测PLA2R抗体<14 RU/ml。
- PLA2R抗体半衰期>7天可识别需额外治疗的患者。
临床怎么用
- 对于高危PLA2R抗体阳性膜性肾病患者,可考虑低剂量三联方案。
- 治疗开始后2-4周监测PLA2R抗体水平,有助于早期识别需更强化治疗的患者。
局限性
- 单臂研究,无对照组。
- 样本量较小(26例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Standard treatment with cyclophosphamide (CP) or rituximab (RTX) is suboptimal. We adapted and used the low-dose regimen used in vasculitis (RTX 2 × 1000 mg, CP 1.5 mg/kg/d × 8 weeks, and prednisone [i.v. 2 × 1 g + 3 weeks oral starting at 1 mg/kg]). METHODS: High-risk, anti-PLA2R antibodies (PLA2Rab)-positive patients with membranous nephropathy (MN) were included in this single-arm prospective cohort study. PLA2Rab levels were regularly measured. We report the PLA2Rab kinetics and overall immunological and clinical remission (CR) rate. RESULTS: We analyzed 26 patients (15 males, aged 57 ± 14 years, PLA2Rab titer 176 [115-460] RU/ml, serum creatinine 128 [102-136] μmol/l, serum albumin 18 [14-21] g/l, and urinary protein-to-creatinine ratio [uPCR] 7.1 [5.7-10] g/10 mmol). Within 8 weeks immunological remission (IR) (enzyme-linked immunosorbent assay < 14 RU/ml) was 88 %. Proteinuria remission after initial therapy developed in 21 patients. Seven patients received renewed therapy, which resulted in proteinuria remission in all. IR and CR were associated with baseline PLA2Rab tertile. Five of 7 patients in need of additional therapy were identified at 4 weeks after start of therapy by PLA2Rab half-life (T1/2) > 7 days. Serious adverse events occurred in 4 patients. Adverse events were mild; leukopenia was most frequent. CONCLUSION: Low-dose triple therapy induced a rapid IR and CR in most patients. Patients with insufficient clinical response were characterized by high baseline PLA2Rab levels and longer PLA2Rab T1/2. Assessment of PLA2Rab levels within 2 to 4 weeks after start of therapy may enable to identify patients who need more intensive therapy.
引用
- Vink CH, Wetzels JFM, Logt AV, et al. Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous Nephropathy. Kidney Int Rep. 2024. PMID: 39698354. doi:10.1016/j.ekir.2024.08.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。